RT @AnnSurgOncol: MARCH ISSUE: #OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative #BreastCancer Patient…
I continue to be fascinated by Oncotype Dx and can’t help but wonder when and if correlations will be made with the Neo-Bioscore now that more and more institutions use it to guide decisions regarding neoadjuvant #chemotherapy
RT @AnnSurgOncol: MARCH ISSUE: #OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative #BreastCancer Patient…
RT @AnnSurgOncol: MARCH ISSUE: #OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative #BreastCancer Patient…
RT @puneetsinghmd: Congrats @SarahTevisMD and colleagues! @KellyKhunt @HenryKuerer @drmediget @EMittendorfMD https://t.co/p2PNb73sNo
RT @EmilJFernando: Great study looking at applications of the #OncotypeDX —> It has not shown to be useful for #decisionmaking regarding ax…
RT @AnnSurgOncol: MARCH ISSUE: #OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative #BreastCancer Patient…
Great study looking at applications of the #OncotypeDX —> It has not shown to be useful for #decisionmaking regarding axillary status or evaluation. Always important to know how to best apply a test! #BreastCancer #Genomics @ASBrS
RT @AnnSurgOncol: MARCH ISSUE: #OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative #BreastCancer Patient…
RT SocSurgOnc RT AnnSurgOncol: MARCH ISSUE: #OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative #BreastCancer Patients.https://t.co/XxecQymNbW McMastersKelly SocSurgOnc https://t.co/MWS5a7S1BC
RT @AnnSurgOncol: MARCH ISSUE: #OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative #BreastCancer Patient…
RT @AnnSurgOncol: MARCH ISSUE: #OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative #BreastCancer Patient…
RT @AnnSurgOncol: MARCH ISSUE: #OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative #BreastCancer Patient…
RT @AnnSurgOncol: MARCH ISSUE: #OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative #BreastCancer Patient…
RT @AnnSurgOncol: MARCH ISSUE: #OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative #BreastCancer Patient…
RT @AnnSurgOncol: MARCH ISSUE: #OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative #BreastCancer Patient…
RT @AnnSurgOncol: MARCH ISSUE: #OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative #BreastCancer Patient…
RT @AnnSurgOncol: MARCH ISSUE: #OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative #BreastCancer Patient…
Surprisingly, Oncotype Dx was not associated with nodal burden in clinically node negative #BreastCancer patients - @SarahTevisMD @AnnSurgOncol #BCSM #SurgOnc #Cancer #BreastSurgery https://t.co/LJBjBe3TaA
Congrats @SarahTevisMD and colleagues! @KellyKhunt @HenryKuerer @drmediget @EMittendorfMD
RT @AnnSurgOncol: MARCH ISSUE: #OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative #BreastCancer Patient…
RT @AnnSurgOncol: MARCH ISSUE: #OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative #BreastCancer Patient…
MARCH ISSUE: #OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative #BreastCancer Patients.https://t.co/LQDXVQ1DC9 @McMastersKelly @SocSurgOnc https://t.co/KPeQiAOoak